Oseltamivir Post-Exposure Prophylaxis for H1N1
For post-exposure prophylaxis against H1N1 influenza, oseltamivir should be initiated within 48 hours of exposure at 75 mg once daily for 7 days in adults and adolescents ≥13 years, with weight-based dosing for children ≥1 year old. 1, 2
Dosing Regimen
Adults and Adolescents (≥13 years)
- Dose: 75 mg once daily
- Duration: 7 days after last known exposure 1, 2
- Timing: Must begin within 48 hours of exposure 1
Pediatric Patients (≥1 year)
Weight-based dosing once daily for 7 days 1, 2:
- ≤15 kg: 30 mg once daily
- 16-23 kg: 45 mg once daily
- 24-40 kg: 60 mg once daily
- >40 kg: 75 mg once daily
Infants (3-11 months)
- 9-11 months: 3.5 mg/kg once daily for 7 days 1
- 3-8 months: 3 mg/kg once daily for 7 days 1
- <3 months: Not recommended unless situation judged critical due to limited safety data 1, 3
Critical Timing Considerations
The 48-hour window is absolute. If more than 48 hours have elapsed since exposure, do not initiate prophylaxis—instead, monitor for symptoms and treat empirically if illness develops 4. This timing constraint is based on the viral replication cycle and when neuraminidase inhibitors can effectively prevent infection establishment.
Special Populations
Institutional Outbreaks
For long-term care facilities or hospital outbreaks, extend prophylaxis for a minimum of 2 weeks and continue for 7 days after the last known case 5, 4. This differs from household exposure where 7-10 days is sufficient 1.
Immunocompromised Patients
Safety has been demonstrated for up to 12 weeks in immunocompromised patients, though standard 7-10 day courses remain appropriate for post-exposure prophylaxis 2.
Renal Impairment
For creatinine clearance 10-30 mL/min, reduce to either 2:
- 75 mg every other day, OR
- 30 mg once daily
Who Should Receive Prophylaxis
Oseltamivir is the preferred agent for post-exposure prophylaxis 1. However, prophylaxis is NOT a substitute for vaccination 1, 2. Reserve prophylaxis for:
- Very high-risk individuals (severely immunocompromised) when vaccination is contraindicated, unavailable, or expected to have low effectiveness 4
- Unvaccinated household contacts of very high-risk persons 4
- All persons exposed to zoonotic influenza (including H5N1), regardless of individual risk 6
The 2024 AAP guidelines emphasize that routine prophylaxis should be limited, as indiscriminate use may promote resistance 1. The evidence from household studies shows 84-89% protective efficacy when used appropriately 7.
Common Pitfalls
Do not confuse prophylaxis dosing with treatment dosing. Prophylaxis is once daily; treatment is twice daily. This error can lead to subtherapeutic dosing for active infection or unnecessary drug exposure during prophylaxis.
Monitor for symptom development during prophylaxis. If symptoms occur, immediately test for influenza and switch to treatment dosing (twice daily) 1, 4. Consider using an antiviral with a different resistance profile if available and not contraindicated 4.
Avoid prophylaxis beyond 48 hours post-exposure as once-daily dosing becomes ineffective at preventing established infection 4. At that point, the strategy shifts to early empiric treatment if symptoms develop.
Administration Details
Oseltamivir may be taken with or without food, though administration with meals may reduce nausea and vomiting 2. The oral suspension (6 mg/mL) is preferred for children who cannot swallow capsules 1. If suspension is unavailable, capsules can be opened and mixed with sweetened liquids 2.
Evidence Quality
The strongest evidence comes from the 2024 AAP guidelines 1 and FDA labeling 2, which supersede older recommendations. A landmark RCT demonstrated 89% individual protective efficacy and 84% household protective efficacy when oseltamivir was given within 48 hours of exposure 7. Nosocomial outbreak data from pediatric wards showed 0% infection rate with prophylaxis versus 69% without it 8, though this was observational data.